Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Giovanni Guaraldi, Ines Pintassilgo, Jovana Milic & Cristina Mussini. (2018) Managing antiretroviral therapy in the elderly HIV patient. Expert Review of Clinical Pharmacology 11:12, pages 1171-1181.
Read now
Read now
Wisit Prasithsirikul, Sukanya Chongthawonsatid, Pirapon June Ohata, Siriwan Keadpudsa, Virat Klinbuayaem, Patsamon Rerksirikul, Stephen J. Kerr, Kiat Ruxrungtham, Jintanat Ananworanich & Anchalee Avihingsanon. (2017) Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand. AIDS Care 29:3, pages 299-305.
Read now
Read now
Razia Gaida, Ilse Truter, Christoffel Grobler, Theunis Kotze & Brian Godman. (2016) A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications. Expert Review of Anti-infective Therapy 14:4, pages 377-388.
Read now
Read now
Crystal C Watkins & Glenn J Treisman. (2015) Cognitive impairment in patients with AIDS – prevalence and severity. HIV/AIDS - Research and Palliative Care 7, pages 35-47.
Read now
Read now
Kit N. Simpson, Kristin A. Hanson, Gale Harding, Seema Haider, Margaret Tawadrous, Alexandra Khachatryan, Chris L. Pashos & Albert W. Wu. (2014) Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden. AIDS Care 26:4, pages 466-475.
Read now
Read now
Eric H Decloedt & Gary Maartens. (2013) Neuronal toxicity of efavirenz: a systematic review. Expert Opinion on Drug Safety 12:6, pages 841-846.
Read now
Read now
Peter Derek Christian Leutscher, Chalotte Stecher, Merete Storgaard & Carsten Schade Larsen. (2013) Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scandinavian Journal of Infectious Diseases 45:8, pages 645-651.
Read now
Read now
Valerio Tozzi, Pietro Balestra, Raffaella Libertone & Andrea Antinori. (2010) Cognitive function in treated HIV patients. Neurobehavioral HIV Medicine 2, pages 95-113.
Read now
Read now
Articles from other publishers (66)
Rebecca Spooner, Sherika Ranasinghe, Sarah Urasa, Marcella Yoseph, Sengua Koipapi, Elizabeta B. Mukaetova-Ladinska, Thomas Lewis, William Howlett, Marieke Dekker, Aloyce Kisoli, William K. Gray, Richard W. Walker, Catherine L. Dotchin, Raj Kalaria, Bingileki Lwezuala, Philip C. Makupa, Rufus Akinyemi & Stella M. Paddick. (2022) HIV-Associated Neurocognitive Disorders: The First Longitudinal Follow-Up of a cART-Treated Cohort of Older People in Sub-Saharan Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes 90:2, pages 214-222.
Crossref
Crossref
Archana Ganapathy, Basavaprabhu Achappa, Vaman Kulkarni, Deepak Madi, Ramesh Holla, Unnikrishnan Bhaskaran, Priya Rathi, Soundarya Mahalingam & Nikhil Victor Dsouza. (2021) Association between Veterans Aging Cohort Study (VACS) index and neurocognitive function among people living with HIV–a cross sectional study in coastal South India. AIDS Research and Therapy 18:1.
Crossref
Crossref
Runji Zhang, Jian Bao, Jialu Qiao, Wenshuang Li, Feng Qian, Kanghong Hu & Binlian Sun. (2021) Long-term efavirenz exposure induced neuroinflammation and cognitive deficits in C57BL/6 mice. Biochemical and Biophysical Research Communications 584, pages 46-52.
Crossref
Crossref
Natália Bordin Andriguetti, Helena Katherina Van Schalkwyk, Daniel Thomas Barratt, Joseph Tucci, Paul Pumuye & Andrew Alexander Somogyi. (2021) Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clinical and Translational Science 14:6, pages 2521-2531.
Crossref
Crossref
Jacinta N. Nwogu, Monica Gandhi, Andrew Owen, Saye H. Khoo, Babafemi Taiwo, Adeniyi Olagunju, Baiba Berzins, Hideaki Okochi, Regina Tallerico, Kevin Robertson & Chinedum P. Babalola. (2021) Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. AIDS 35:12, pages 1919-1927.
Crossref
Crossref
Shilpa Sonti, Adhikarimayum Lakhikumar Sharma & Mudit Tyagi. (2021) HIV-1 persistence in the CNS: Mechanisms of latency, pathogenesis and an update on eradication strategies. Virus Research 303, pages 198523.
Crossref
Crossref
Dong-Qin Yan, Yun-Xiang Huang, Xi Chen, Min Wang, Jie Li & Dan Luo. (2021) Application of the Chinese Version of the Pittsburgh Sleep Quality Index in People Living With HIV: Preliminary Reliability and Validity. Frontiers in Psychiatry 12.
Crossref
Crossref
Leah H. Rubin, Yuliang Li, Kathryn C. Fitzgerald, Raha Dastgheyb, Amanda B. Spence, Pauline M. Maki, Anjali Sharma, Deborah R. Gustafson, Joel Milam, Kathleen M. Weber, Adaora A. Adimora, Norman J. Haughey, Igho Ofotokun, Margaret A. Fischl, Deborah Konkle-Parker, Yanxun Xu & Dionna W. Williams. (2020) Associations between Antiretrovirals and Cognitive Function in Women with HIV. Journal of Neuroimmune Pharmacology 16:1, pages 195-206.
Crossref
Crossref
Brice Faraut, Lorenzo Tonetti, Alexandre Malmartel, Sophie Grabar, Jade Ghosn, Jean-Paul Viard, Vincenzo Natale & Damien Léger. (2021) Sleep, Prospective Memory, and Immune Status among People Living with HIV. International Journal of Environmental Research and Public Health 18:2, pages 438.
Crossref
Crossref
Asante R. Kamkwalala, Kunbo Wang, Jane O’Halloran, Dionna W. Williams, Raha Dastgheyb, Kathryn C. Fitzgerald, Amanda B. Spence, Pauline M. Maki, Deborah R. Gustafson, Joel Milam, Anjali Sharma, Kathleen M. Weber, Adaora A. Adimora, Igho Ofotokun, Anandi N. Sheth, Cecile D. Lahiri, Margaret A. Fischl, Deborah Konkle-Parker, Yanxun Xu & Leah H. Rubin. (2020) Starting or Switching to an Integrase Inhibitor-Based Regimen Affects PTSD Symptoms in Women with HIV. AIDS and Behavior 25:1, pages 225-236.
Crossref
Crossref
Phillip Chan, Orlanda Goh, Eugène Kroon, Donn Colby, Carlo Sacdalan, Suteeraporn Pinyakorn, Peeriya Prueksakaew, Peter Reiss, Jintanat Ananworanich, Victor Valcour, Serena Spudich & Robert Paul. (2020) Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort. AIDS Research and Therapy 17:1.
Crossref
Crossref
Alyssa Vecchio, Kevin Robertson, Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Alice Kisakye, James Batte, Richard Mayanja, Aggrey Anok, Steven J. Reynolds, Thomas C. Quinn, Ronald Gray, Maria J. Wawer, Ned Sacktor & Leah H. Rubin. (2020) Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda. JAIDS Journal of Acquired Immune Deficiency Syndromes 84:5, pages 534-542.
Crossref
Crossref
O. D. OstroumovaC. V. Batyukina, E. Yu. Ebzeeva & N. A. Shatalova. (2020) Medications associated with development of drug-induced depression. Medical alphabet 1:11, pages 36-45.
Crossref
Crossref
Xueling Xiao, Hui Zeng, Caiyun Feng, Hang Tan, Lanlan Wu, Hui Zhang, Mary-Lynn Brecht, Honghong Wang & Deborah Koniak-Griffin. (2020) Cognitive Impairment Among Aging People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Hunan, China. Journal of the Association of Nurses in AIDS Care 31:3, pages 301-311.
Crossref
Crossref
Josué Jeyzon de Lima Soares Valeriano, Wlisses Henrique Veloso Carvalho-Silva, Antônio Victor Campos Coelho, Ronald Rodrigues Moura, Luiz Cláudio Arraes, Lucas André Cavalcanti Brandão, Sergio Crovella & Rafael Lima Guimarães. (2020) Increased risk of dizziness in human immunodeficiency virus-infected patients taking zidovudine and efavirenz combination: a Brazilian cohort study. Journal of Pharmacy and Pharmacology 72:5, pages 719-727.
Crossref
Crossref
Aaron Richterman & Paul E. Sax. (2020) Antiretroviral therapy in older people with HIV. Current Opinion in HIV and AIDS 15:2, pages 118-125.
Crossref
Crossref
Tomohiro Hosoda, Yuki Uehara & Toshio Naito. (2020) An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir. Internal Medicine 59:2, pages 285-287.
Crossref
Crossref
Giuseppe Lapadula, Davide Paolo Bernasconi, Francesca Bai, Emanuele Focà, Antonio Di Biagio, Stefano Bonora, Francesco Castelli, Nicola Squillace, Alessandra Bandera, Antonella d’Arminio Monforte, Guglielmo Marco Migliorino & Andrea Gori. (2020) Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. AIDS 34:1, pages 53-61.
Crossref
Crossref
Sipho Mdanda, Sphamandla Ntshangase, Sanil D. Singh, Tricia Naicker, Hendrik G. Kruger, Sooraj Baijnath & Thavendran Govender. (2019) Investigating time dependent brain distribution of nevirapine via mass spectrometric imaging. Journal of Molecular Histology 50:6, pages 593-599.
Crossref
Crossref
Vera, Bracchi, Alagaratnam, Lwanga, Fox, Winston, Boffito & Nelson. (2019) Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART. Brain Sciences 9:8, pages 195.
Crossref
Crossref
Jane A. O’Halloran, Sarah A. Cooley, Jeremy F. Strain, Anna Boerwinkle, Robert Paul, Rachel M. Presti & Beau M. Ances. (2019) Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors. AIDS 33:9, pages 1477-1483.
Crossref
Crossref
Yijia Li, Zheng Wang, Yu Cheng, James T. Becker, Eileen Martin, Andrew Levine, Leah H. Rubin, Ned Sacktor, Ann Ragin & Ken Ho. (2019) Neuropsychological changes in efavirenz switch regimens. AIDS 33:8, pages 1307-1314.
Crossref
Crossref
Kay Seden, Daniel Kiiza, Eva Laker, Walter J Arinaitwe, Catriona Waitt, Mohammed Lamorde & Saye Khoo. (2018) High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily. Journal of Antimicrobial Chemotherapy 73:11, pages 3158-3161.
Crossref
Crossref
Marijana Vujkovic, Scarlett L. Bellamy, Athena F. Zuppa, Marc R. Gastonguay, Ganesh S. Moorthy, Bakgaki Ratshaa, Xiaoyan Han, Andrew P. Steenhoff, Mosepele Mosepele, Brian L. Strom, Gregory P. Bisson, Richard Aplenc & Robert Gross. (2018) Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana. The Pharmacogenomics Journal 18:5, pages 678-688.
Crossref
Crossref
Brice Faraut, Alexandre Malmartel, Jade Ghosn, Martin Duracinsky, Damien Leger, Sophie Grabar & Jean-Paul Viard. (2018) Sleep Disturbance and Total Sleep Time in Persons Living with HIV: A Cross-Sectional Study. AIDS and Behavior 22:9, pages 2877-2887.
Crossref
Crossref
Watsamon Jantarabenjakul, Suvaporn Anugulruengkitt, Naruporn Kasipong, Narukjaporn Thammajaruk, Jiratchaya Sophonphan, Torsak Bunupuradah, Tim R Cressey, Angela Colbers, David M Burger, Wanatpreeya Phongsamart, Thanyawee Puthanakit & Chitsanu Pancharoen. (2017) Pharmacokinetics of Rilpivirine and 24-Week Outcomes after Switching from Efavirenz in Virologically Suppressed HIV-1-Infected Adolescents. Antiviral Therapy 23:3, pages 259-265.
Crossref
Crossref
Norma Kabuba, J. Anitha Menon, Donald R. FranklinJr.Jr., Robert K. Heaton & Knut A. Hestad. (2016) Use of Western Neuropsychological Test Battery in Detecting HIV-Associated Neurocognitive Disorders (HAND) in Zambia. AIDS and Behavior 21:6, pages 1717-1727.
Crossref
Crossref
Uriel Sandkovsky, Anthony T. Podany, Courtney V. Fletcher, Andrew Owen, Angela Felton-Coleman, Lee C. Winchester, Kevin Robertson & Susan Swindells. (2017) Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. Journal of Antimicrobial Chemotherapy 72:1, pages 200-204.
Crossref
Crossref
Juan TiraboschiLisa HamzahAlastair TeagueRanjababu KulasegaramFrank PostIsabelle JendruleckTammy MurrayJulie Fox. (2016) Short Communication: The Impact of Switching from Atripla to Darunavir/Ritonavir Monotherapy on Neurocognition, Quality of Life, and Sleep: Results from a Randomized Controlled Study. AIDS Research and Human Retroviruses 32:12, pages 1198-1201.
Crossref
Crossref
Thomas Tesson, Mathieu Blot, Aurélie Fillion, Hama Djerad, Joséphine Cagnon-Chapalain, Aline Creuwels, Anne Waldner, Michel Duong, Marielle Buisson, Sophie Mahy, Pascal Chavanet & Lionel Piroth. (2015) Duration of First-Line Antiretroviral Therapy in HIV-Infected Treatment-Naive Patients in Routine Practice. Antiviral Therapy 21:8, pages 715-724.
Crossref
Crossref
Glenn J. Treisman & Olivia Soudry. (2016) Neuropsychiatric Effects of HIV Antiviral Medications. Drug Safety 39:10, pages 945-957.
Crossref
Crossref
Razia Gaida, Ilse Truter & Christoffel Grobler. (2016) Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape. Southern African Journal of HIV Medicine 17:1.
Crossref
Crossref
Charles K Hammond, Brian Eley & Jo M Wilmshurst. (2016) Neuropsychiatric complications of efavirenz in children with HIV infection. Future Virology 11:6, pages 469-480.
Crossref
Crossref
Qing Ma, Florin Vaida, Jenna Wong, Chelsea A. Sanders, Yu-ting Kao, David Croteau, David B. Clifford, Ann C. Collier, Benjamin B. Gelman, Christina M. Marra, Justin C. McArthur, Susan Morgello, David M. Simpson, Robert K. Heaton, Igor Grant & Scott L. Letendre. (2015) Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. Journal of NeuroVirology 22:2, pages 170-178.
Crossref
Crossref
C. Allavena, T. Guimard, E. Billaud, S. De la Tullaye, V. Reliquet, S. Pineau, H. Hüe, C. Supiot, J.-M. Chennebault, C. Michau, H. Hitoto, R. Vatan & F. Raffi. (2015) Prevalence and Risk Factors of Sleep Disturbance in a Large HIV-Infected Adult Population. AIDS and Behavior 20:2, pages 339-344.
Crossref
Crossref
Milcah Dhoro, Simbarashe Zvada, Bernard Ngara, Charles Nhachi, Gerald Kadzirange, Prosper Chonzi & Collen Masimirembwa. (2015) CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacology and Toxicology 16:1.
Crossref
Crossref
Francoise Pinillos, Collet Dandara, Marelize Swart, Renate Strehlau, Louise Kuhn, Faeezah Patel, Ashraf Coovadia & Elaine Abrams. (2016) Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation. BMC Infectious Diseases 16:1.
Crossref
Crossref
Noris Pavia-Ruz, Magdel Rossouw, Xavier Sáez-Llorens, Torsak Bunupuradah, Mathew Taylor, Rong Yang, Heather Sevinsky, Mark Krystal, Max Lataillade, Daniel Seekins & Sophie Biguenet. (2015) Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age. Pediatric Infectious Disease Journal 34:12, pages 1355-1360.
Crossref
Crossref
Nadezda Apostolova, Haryes A. Funes, Ana Blas-Garcia, Maria J. Galindo, Angeles Alvarez & Juan V. Esplugues. (2015) Efavirenz and the CNS: what we already know and questions that need to be answered. Journal of Antimicrobial Chemotherapy 70:10, pages 2693-2708.
Crossref
Crossref
Nathan Ford, Zara Shubber, Anton Pozniak, Marco Vitoria, Meg Doherty, Catherine Kirby & Alexandra Calmy. (2015) Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 69:4, pages 422-429.
Crossref
Crossref
Ellen M. McDonagh, Johnathan L. Lau, Maria L. Alvarellos, Russ B. Altman & Teri E. Klein. (2015) PharmGKB summary. Pharmacogenetics and Genomics 25:7, pages 363-376.
Crossref
Crossref
Mark R. Etherton, Jennifer L. Lyons & Kevin L. Ard. (2015) HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies. Current Infectious Disease Reports 17:6.
Crossref
Crossref
Arthur A. Simen, Junshui Ma, Vladimir Svetnik, David Mayleben, James Maynard, Adam Roth, Lori Mixson, Robin Mogg, David Shera, Laura George, T. Chris Mast, Chan Beals, Aubrey Stoch, Arie Struyk, Norah Shire & Iain Fraser. (2015) Efavirenz modulation of sleep spindles and sleep spectral profile. Journal of Sleep Research 24:1, pages 66-73.
Crossref
Crossref
Maria Giulia Nanni, Rosangela Caruso, Alex J. Mitchell, Elena Meggiolaro & Luigi Grassi. (2014) Depression in HIV Infected Patients: a Review. Current Psychiatry Reports 17:1.
Crossref
Crossref
G Tudor-Williams, P Cahn, K Chokephaibulkit, J Fourie, C Karatzios, S Dincq, M Opsomer, TN Kakuda, S Nijs, L Tambuyzer & FL Tomaka. (2014) Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. HIV Medicine 15:9, pages 513-524.
Crossref
Crossref
Dixon Chibanda, Laura Benjamin, Helen A. Weiss & Melanie Abas. (2014) Mental, Neurological, and Substance Use Disorders in People Living With HIV/AIDS in Low- and Middle-Income Countries. JAIDS Journal of Acquired Immune Deficiency Syndromes 67:Supplement 1, pages S54-S67.
Crossref
Crossref
F Gutiérrez, L García, S Padilla, D Álvarez, S Moreno, G Navarro, JL Gómez-Sirvent, F Vidal, V Asensi & M Masiá. (2014) Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs. HIV Medicine 15:4, pages 213-223.
Crossref
Crossref
Nathan Ford, Lynne Mofenson, Zara Shubber, Alexandra Calmy, Isabelle Andrieux-Meyer, Marco Vitoria, Nathan Shaffer & Françoise Renaud. (2014) Safety of efavirenz in the first trimester of pregnancy. AIDS 28, pages S123-S131.
Crossref
Crossref
Michael S. Abers, Wayne X. Shandera & Joseph S. Kass. (2013) Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs. CNS Drugs 28:2, pages 131-145.
Crossref
Crossref
Anton Pozniak, Simon Rackstraw, Jane Deayton, Tristan Barber, Steve Taylor, Hadi Manji, Diane Melvin, Michelle Croston, Sam Nightingale, Ranubabu Kulasegaram, Mervi Pitkanen & Alan Winston. (2014) Hiv-Associated Neurocognitive Disease: Case Studies and Suggestions for Diagnosis and Management in Different Patient Subgroups. Antiviral Therapy 19:1, pages 1-13.
Crossref
Crossref
Inmaculada Poquet, Marine Bourguet, Simona Cioaia & Carlos Tornero. (2014) Alteraciones en las habilidades para la conducción en pacientes que inician tratamiento con efavirenz. Enfermedades Infecciosas y Microbiología Clínica 32:1, pages 59-60.
Crossref
Crossref
Kit N Simpson, Kristin A Hanson, Gale Harding, Seema Haider, Margaret Tawadrous, Alexandra Khachatryan, Chris L Pashos & Albert W Wu. (2013) Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review. Health and Quality of Life Outcomes 11:1.
Crossref
Crossref
David B Clifford & Beau M Ances. (2013) HIV-associated neurocognitive disorder. The Lancet Infectious Diseases 13:11, pages 976-986.
Crossref
Crossref
Serena Spudich. (2013) HIV and Neurocognitive Dysfunction. Current HIV/AIDS Reports 10:3, pages 235-243.
Crossref
Crossref
Charlene E. Gamaldo, Alyssa Gamaldo, Jason Creighton, Rachel E. Salas, Ola A. Selnes, Paula M. David, Gilbert Mbeo, Benjamin S. Parker, Amanda Brown, Justin C. McArthur & Michael T. Smith. (2013) Evaluating Sleep and Cognition in HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 63:5, pages 609-616.
Crossref
Crossref
AM Mills, A Antinori, B Clotet, J Fourie, G Herrera, C Hicks, JV Madruga, S Vanveggel, M Stevens & K Boven. (2013)
Neurological and psychiatric tolerability of rilpivirine (TMC278)
vs.
efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks
. HIV Medicine 14:7, pages 391-400.
Crossref
Crossref
Charles T UptonBabafemi Taiwo & Kevin R Robertson. (2013) Neurotoxicity of antiretroviral therapy. Future Virology 8:5, pages 469-475.
Crossref
Crossref
A. Antinori, G. Arendt, I. Grant, S. Letendre, Chair, J. A. Munoz-Moreno, C. Eggers, B. Brew, M.-J. Brouillette, F. Bernal-Cano, A. Carvalhal, P. P. Christo, P. Cinque, L. Cysique, R. Ellis, I. Everall, J. Gasnault, I. Husstedt, V. Korten, L. Machala, M. Obermann, S. Ouakinin, D. Podzamczer, P. Portegies, S. Rackstraw, S. Rourke, L. Sherr, A. Streinu-Cercel, A. Winston, V. Wojna, Y. Yazdanpannah, G. Arbess, J.-G. Baril, J. Begovac, C. Bergin, P. Bonfanti, S. Bonora, K. Brinkman, A. Canestri, G. Cholewinska-Szymanska, M. Chowers, J. Cooney, M. Corti, C. Doherty, D. Elbirt, S. Esser, E. Florence, G. Force, J. Gill, J.-C. Goffard, T. Harrer, P. Li, L. V. de Kerckhove, G. Knecht, S. Matsushita, R. Matulionyte, S. McConkey, A. Mouglignier, S. Oka, A. Penalva, K. Riesenberg, H. Sambatakou, V. Tozzi, M. Vassallo, P. Wetterberg & A. W. Drapato. (2012) Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program. Clinical Infectious Diseases 56:7, pages 1004-1017.
Crossref
Crossref
Gilbert Seda, Teofilo Lee-Chiong & John Harrington. (2012) Sleep Derangements in Central Nervous System Infections. Sleep Medicine Clinics 7:4, pages 703-711.
Crossref
Crossref
Shahin Lockman & Paul Sax. (2012) Treatment-for-prevention. Current Opinion in HIV and AIDS 7:2, pages 131-139.
Crossref
Crossref
Kenneth D. Gadow, Konstantia Angelidou, Miriam Chernoff, Paige L. Williams, Jerry Heston, Janice Hodge & Sharon Nachman. (2012) Longitudinal Study of Emerging Mental Health Concerns in Youth Perinatally Infected With HIV and Peer Comparisons. Journal of Developmental & Behavioral Pediatrics 33:6, pages 456-468.
Crossref
Crossref
Renate Strehlau, Leigh Martens, Ashraf Coovadia, Collet Dandara, Jennifer Norman, Julia Maisel, Louise Kuhn & Elaine J. Abrams. (2011) Absence Seizures Associated With Efavirenz Initiation. Pediatric Infectious Disease Journal 30:11, pages 1001-1003.
Crossref
Crossref
N. CiccarelliM. FabbianiS. Di GiambenedettoI. FantiE. BaldoneroL. BraccialeE. TamburriniR. CaudaA. De LucaM.C. Silveri. (2011) Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76:16, pages 1403-1409.
Crossref
Crossref
Judith Schouten, Paola Cinque, Magnus Gisslen, Peter Reiss & Peter Portegies. (2011) HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 25:5, pages 561-575.
Crossref
Crossref
Laura Waters, Martin Fisher, Alan Winston, Chris Higgs, Wendy Hadley, Lucy Garvey, Sundhiya Mandalia, Nicky Perry, Mackie Nicola & Mark Nelson. (2011) A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 25:1, pages 65-71.
Crossref
Crossref
Thomas Ruzicka, Hans Wolff, Peter Thomas & Jörg Prinz. 2011. Fortschritte der praktischen Dermatologie und Venerologie. Fortschritte der praktischen Dermatologie und Venerologie
269
546
.